Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMFORT Toddlers
2025-521697-34-00Phase 3Authorised
- Sponsor
- DBV Technologies
- Start
- Oct 2025
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing Viaskin Peanut with Placebo patch (2 arms). Primary endpoints: Adverse events and treatment-emergent adverse events by system organ class and preferred term, Treatment-emergent adverse events by maximum severity, duration, and relatedness and 10 more. Planned start Oct 2025; status: authorised.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2025-521697-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521697-34-00.